Why settle for conventional quality control when you can detect trace amounts of biological contaminants with confidence?
Bioprocessing encompasses a plethora of methodologies and activities designed to derive value-added products from biological systems (organisms, cells, or subcellular components). Today, it is indispensable in the production of pharmaceuticals, foods and food components, fuels, and chemicals. Fractionation and purification are key stages in bioprocessing, with extremely strict purity requirements applying to some types of final product.
Molecular biology techniques are increasingly applied in the quality control of bioproducts due to scalability and sensitivity. Bulk sampling is routinely employed for practical reasons, but limits the sensitivity with which very low levels of contaminants can be detected.
BioSkryb’s ResolveDNA™ amplification technology (PTA) enables the researcher to peer into genomic space for applications that require precise definition of genomic integration or editing coordinates. The emergence of CRISPR gene editing into the forefront of research space will require more comprehensive assessment of off-target edits moving forward, and, eventually, routine genome-wide assessment of these off-targets. Similarly, for AAV-based gene therapy and chimeric antigen receptor (CAR) research it is crucial to understand the functional implications of the integration site on the vector itself in terms of its transgene expression and stability, as well as to understand the potential deleterious effects of integration on endogenous gene expression and regulation at both proximal and distal loci. ResolveDNA importantly allows the researcher to assess these effects at the single-cell and clonal levels.